Cogent Biosciences (COGT) Accounts Payables (2017 - 2026)

Cogent Biosciences' Accounts Payables history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 2.9% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (down 2.9% YoY), while the FY2025 annual figure was $9.5 million, down 20.89% from the prior year.
• Accounts Payables was $13.7 million for Q1 2026 at Cogent Biosciences, up from $9.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $16.6 million in Q2 2025 to a low of $3.5 million in Q2 2022.
• Historically, Accounts Payables has averaged $10.1 million across 5 years, with a median of $9.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 1174.6% in 2022, then decreased 20.89% in 2025.
• A 5-year view of Accounts Payables shows it stood at $5.8 million in 2022, then jumped by 82.39% to $10.7 million in 2023, then advanced by 12.75% to $12.0 million in 2024, then fell by 20.89% to $9.5 million in 2025, then jumped by 44.61% to $13.7 million in 2026.
• The last three Accounts Payables figures came in at $13.7 million (Q1 2026), $9.5 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.